181 related articles for article (PubMed ID: 29529123)
1. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis.
Woolridge KF; Boler PL; Lee BD
Cutis; 2018 Jan; 101(1):E15-E21. PubMed ID: 29529123
[TBL] [Abstract][Full Text] [Related]
2. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review.
Zhang S; Tang S; Li S; Pan Y; Ding Y
J Dermatolog Treat; 2020 Feb; 31(1):66-73. PubMed ID: 30702955
[No Abstract] [Full Text] [Related]
3. TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis.
Nwikue G; Olsson-Brown A; Aboheimed N; Yip V; Jolly C; Luchian A; Ressel L; Sharma A; Bergfeld W; Ahmed S; Dickinson A; Pirmohamed M; Carr DF
J Dermatol; 2023 Sep; 50(9):1129-1139. PubMed ID: 37269158
[TBL] [Abstract][Full Text] [Related]
4. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
[TBL] [Abstract][Full Text] [Related]
5. Levetiracetam-induced pediatric toxic epidermal necrolysis successfully treated with etanercept.
Estébanez A; Sáez-Martín LC; Muñoz JI; Silva E; Monrabal A; Monteagudo C; Ramón MD
Pediatr Dermatol; 2020 Jul; 37(4):701-705. PubMed ID: 32319121
[TBL] [Abstract][Full Text] [Related]
6. Pediatric toxic epidermal necrolysis treated successfully with infliximab.
Chafranska L; Saunte DM; Behrendt N; Nygaard U; Christensen RJ; Sand C; Jemec GB
Pediatr Dermatol; 2019 May; 36(3):342-345. PubMed ID: 30834560
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic potential of TNF-α antagonists in toxic epidermal necrosis: insights from two cases and adverse event reports.
Vural S; Arakawa A; Arakawa Y; Prinz JC
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):e418-e419. PubMed ID: 29705991
[No Abstract] [Full Text] [Related]
8. Pediatric Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Halted by Etanercept.
Gavigan GM; Kanigsberg ND; Ramien ML
J Cutan Med Surg; 2018; 22(5):514-515. PubMed ID: 29421925
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases.
Heidelberger V; Ingen-Housz-Oro S; Marquet A; Mahevas M; Bessis D; Bouillet L; Caux F; Chapelon-Abric C; Debarbieux S; Delaporte E; Duval-Modeste AB; Fain O; Joly P; Marchand-Adam S; Monfort JB; Noël N; Passeron T; Ruivard M; Sarrot-Reynauld F; Verrot D; Bouvry D; Fardet L; Chosidow O; Sève P; Valeyre D
JAMA Dermatol; 2017 Jul; 153(7):681-685. PubMed ID: 28564695
[TBL] [Abstract][Full Text] [Related]
10. The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential.
So N; Leavitt E; Aleshin M; Worswick S
Dermatol Ther; 2018 Sep; 31(5):e12684. PubMed ID: 30175438
[TBL] [Abstract][Full Text] [Related]
11. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Treatment With a Biologic: A Case Report.
Chong I; Chao A
Perm J; 2017; 21():16-060. PubMed ID: 28488978
[TBL] [Abstract][Full Text] [Related]
12. A new case series on etanercept treatment for toxic epidermal necrolysis.
Paradisi A; Abeni D; Didona D; Ricci F; Canzona F; Didona B
Eur J Dermatol; 2020 Oct; 30(5):561-568. PubMed ID: 33021477
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide in toxic epidermal necrolysis.
Klausner JD; Kaplan G; Haslett PA
Lancet; 1999 Jan; 353(9149):324. PubMed ID: 9929047
[No Abstract] [Full Text] [Related]
14. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
Wang CW; Yang LY; Chen CB; Ho HC; Hung SI; Yang CH; Chang CJ; Su SC; Hui RC; Chin SW; Huang LF; Lin YY; Chang WY; Fan WL; Yang CY; Ho JC; Chang YC; Lu CW; Chung WH;
J Clin Invest; 2018 Mar; 128(3):985-996. PubMed ID: 29400697
[TBL] [Abstract][Full Text] [Related]
15. Toxic epidermal necrolysis in a child successfully treated with infliximab.
Scott-Lang V; Tidman M; McKay D
Pediatr Dermatol; 2014; 31(4):532-4. PubMed ID: 23072342
[TBL] [Abstract][Full Text] [Related]
16. Review of Toxic Epidermal Necrolysis.
Harris V; Jackson C; Cooper A
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999358
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-α inhibitor for successful treatment of toxic epidermal necrolysis with severe infection: a case series.
Peng YT; Xiong JX; Wei B; Li H; Xu J; Chen AJ; Wang P
J Int Med Res; 2024 Jan; 52(1):3000605231223059. PubMed ID: 38296223
[TBL] [Abstract][Full Text] [Related]
18. Severe cutaneous adverse reactions to drugs.
Chia FL; Leong KP
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):304-9. PubMed ID: 17620821
[TBL] [Abstract][Full Text] [Related]
19. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study.
Paquet P; Jennes S; Rousseau AF; Libon F; Delvenne P; Piérard GE
Burns; 2014 Dec; 40(8):1707-12. PubMed ID: 24726294
[TBL] [Abstract][Full Text] [Related]
20. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis.
Fischer M; Fiedler E; Marsch WC; Wohlrab J
Br J Dermatol; 2002 Apr; 146(4):707-9. PubMed ID: 11966713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
